Skip to main content
Explore URMC

menu

A Drug Study of Ibrutinib + Obinutuzumab in Patients with Chronic Lymphocytic Leukemia (CLL)

Research Question:
What is the effect of the combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).

Basic Study Information

Purpose:
This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).

Location: University of Rochester Medical Center
Study Reference #: ULYM17O45

Lead Researcher (Principal Investigator)

Lead Researcher: Paul Barr

Study Contact Information

Study Coordinator: Andrew Bui
Phone: (585) 276-4405
Email: Andrew_Bui@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search